C · T · M
Christopher Thomas, Michael Weed, Sanford Perl, Daniella Vespoli
January 24, 2026
Kirkland Advises GTCR on Strategic Investment in Resonetics by Carlyle
1 min
AI-made summary
- Kirkland & Ellis represented GTCR and its portfolio company, Resonetics, in the sale of a minority equity stake in Resonetics to funds affiliated with Carlyle, a global investment firm
- The transaction values Resonetics at approximately $2.25 billion
- Following the deal, Carlyle will become a significant shareholder alongside GTCR
- The Kirkland & Ellis team was led by corporate partners Christopher Thomas, Michael Weed, Sanford Perl, and associate Daniella Vespoli.
Kirkland & Ellis advised GTCR, a leading private equity firm, and its portfolio company, Resonetics, on the sale of a minority equity stake in Resonetics to funds affiliated with global investment firm Carlyle (NASDAQ: CG), valuing Resonetics at approximately $2.25 billion. Carlyle will join GTCR as a meaningful shareholder in Resonetics as a result of the transaction. Read the GTCR press release The Kirkland team was led by corporate partners Christopher Thomas, Michael Weed and Sanford Perl and associate Daniella Vespoli.
C
Article Author
Christopher Thomas, Michael Weed, Sanford Perl, Daniella Vespoli
The Sponsor